Hormone receptor expression in craniopharyngiomas: A clinicopathological correlation

Neurosurgery

Volumn 67, Issue 3, 2010, Pages 617-625

  Hofmann, Bernd M ^a,b   Hoelsken, Annett ^a   Fahlbusch, Rudolf ^a,c   Blümcke, Ingmar ^a   Buslei, Rolf ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SIEMENS AG   (Germany)

^c INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

Author keywords

Craniopharyngioma; Endocrinology; Hormonal receptors; Immunohistochemistry; Tumor

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GROWTH FACTOR; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; LEPTIN; PROGESTERONE; SOMATOMEDIN C;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ARTICLE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CRANIOPHARYNGIOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR GENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TUMOR RECURRENCE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CRANIOPHARYNGIOMA; FEMALE; HORMONES; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77956191067     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000372918.68453.5B     Document Type: Article

References (45)

1. Adamson TE, Wiestler OD, Kleihues P, Yaargil MG. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg. 1990;73(1):12-17.
2. Hoffmann HJ, De Silva M, Humphreys R P, Drake JM, Smith ML, Blaser SI. Aggressive surgical management of craniopharyngiomas in children. J Neurosurg. 1992;76(1):47-52.
3. Fahlbusch R, Honegger J, Paulus W, Huk WJ, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg. 1999;90(2):237-250.
4. Chakrabarti I, Amar A P, Couldwell W, Weiss MH. Long-term neurological, visual, and endocrine outcomes following transnasal resection of craniopharyngioma. J Neurosurg. 2005;102(4):650-657.
5. Duff JM, Meyer FB, Ilstrup DM, Laws ER Jr, Schleck CD, Scheithauer BW. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery. 2000;46(2):291-305.
6. Karavitaki N, Brufani C, Warner J T, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf). 2005;62(4):397-409.
7. Úlfarsson E, Lindquist C, Roberts M, et al. Gamma knife radiosurgery for cran-iopharyngiomas: long-term results in the first Swedish patients. J Neurosurg. 2002;97(5)(suppl):613-622.
8. Isaac MA, Hahn SS, Kim JAC, Bogart JA, Chung CT. Management of cranio-pharyngioma. Cancer J. 2001;7(6):516-520.
9. Kobayashi T, Kida Y, Mori Y, Hasegawa T. Long-term results of gamma knife surgery for the treatment of craniopharyngioma in 98 consecutive cases. J Neurosurg. 2005;103(6)(suppl):482-488.
10. Poretti A, Grotzer MA, Ribi K, Schonle E, Boltshauser E. Outcome of cranio-pharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol. 2004;46(4):220-229.
11. Verhelst JA, Kendall-Taylor P, Erfurth EM, et al. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International metabolic disease). J Clin Endocrinol Metab. 2005;90(8):4636-4643.
12. Honegger J, Buchfelder M, Fahlbusch R. Surgical treatment of craniopharyn-giomas: endocrinological results. J Neurosurg. 1999;90(2):251-257.
13. Gonc EN, Yordam N, Ozon A, Alikasifoglu A, Kandemir N. Endocrinological outcome of different treatment options in children with craniopharyngioma: a retrospective analysis of 66 cases. Pediatr Neurosurg. 2004;40(3):112-119.
14. Abe T, Luedecke DK. Transnasal surgery for infradiaphragmatic craniopharyn-giomas in pediatric patients. Neurosurgery. 1999;44(5):957-966.
15. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngiomas. J Neurosurg. 1998;89(4):547-551.
16. Schoenle EJ, Zapf J, Prader A, Torresani T, Werder EA, Zachmann M. Replacement of growth hormone (GH) in normally growing GH-deficient patients operated for craniopharyngioma. J Clin Endocrinol Metab. 1995;80(2):374-378.
17. Geffner M, Lundberg M, Koltowska-Häggström M, et al. Changes in height, weight and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International growth database). J Clin Endocrinol Metab. 2004;89(11):5435-5440.
18. Pinto G, Bussieres L, Recasens C, Souberbielle JC, Zerah M, Brauner R. Hormonal factors influencing weight and growth pattern in craniopharyngioma. Horm Res. 2000;53(4):163-169.
19. Hogeveen M, Noordam C, Otten B, Wit JM, Massa G. Growth before and during growth hormone treatment in children operated for craniopharyngiomas. Horm Res. 1997;48(6):258-262.
20. Niu DM, Guo WY, Pan HC, Wong TT. Rapid enlargement of a residual cranio-pharyngioma during short-term growth hormone replacement. Child's Nerv Syst. 2002;18(3-4):164-165.
21. Price DA, Wilton P, Jönsson P, et al. Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996. Horm Res. 1998;49(2):91-97.
22. Karavitaki N, Warner JT, Marland A, et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngiom. Clin Endocrinol (Oxf). 2006;64(5):556-560.
23. Chung T T, Drake WM, Evanson J, et al. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin Endocrinol (Oxf). 2005;63(3):274-279.
24. Maneatis T, Baptista J, Conelly K, Blethen S. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab. 2000; 13(2)(suppl):1035-1044.
25. Abs R, Bengtsson BA, Hernberg-Stahl E, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf). 1999;50(6):703-713.
26. Frajese G, Drake WM, Loureiro RA, et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab. 2001;86(11):5172-5175.
27. Darendeliler F, Karagiannis G, Wilton P, et al. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr Scand. 2006;95(10):1284-1290.
28. Ulfarsson E, Karström A, Yin S, et al. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin Cancer Res. 2005;11(13):4674-4680.
29. Uchino Y, Saeki N, Iwadate Y, et al. Recurrence of sellar and suprasellar tumors in children treated with hGH-relation to immunohistochemical study on GH receptor. Endocr J. 2000;47(suppl):33-36.
30. Izumoto S, Suzuki T, Kinoshita M, et al. Immunohistochemical detection of female sex hormone receptors in craniopharyngioma: correlation with clinical and histo-logic features. Surg Neurol. 2005;63(6):520-525.
31. Thapar K, Stefaneanu L, Kovacs K, et al. Estrogen receptor gene expression in craniopharyngiomas: an in situ hybridization study. Neurosurgery. 1994;35(6):1012-1017.
32. Honegger J, Renner C, Fahlbusch R, Adams E F. Progesterone receptor gene expression in craniopharyngiomas and evidence for biological activity. Neurosurgery. 1997;41(6):1359-1364.
33. Hofmann BM, Kreutzer J, Saeger W, et al. Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and Rathke cleft cysts: a clinico-pathologic approach. Am J Surg Pathol. 2006;30(12):1595-1603.
34. Buslei R, Holsken A, Hofmann B, et al. Nuclear beta-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas. Acta Neuropathol. 2007;113(5):585-590.
35. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC; 2000.
36. Buslei R, Kreutzer J, Hofmann B, et al. Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas. Acta Neuropathol. 2006;111(3):1-8.
37. Clausen LR, Kristiansen MT, Rasmussen LM, et al. Growth hormone receptor expression and function in pituitary adenomas. Clin Endocrinol (Oxf). 2004;60(5):578-583.
38. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Med. 1997;3(10):1141-1144.
39. Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L. Morphological and ultrastructural findings of prognostic impact in craniopharyn-giomas. Ultrastruct Pathol. 2006;30(3):143-150.
40. Jin L, Burguera BG, Couce ME, et al. Leptin and leptin receptor expression in normal and neoplastic pituitary: evidence of a regulatory role for leptin on pituitary cell proliferation. J Clin Endocrinol Metab. 1999;84(8):2903-2911.
41. Tsumanuma I, Jin L, Zhang S, Bayliss JM, Scheithauer BW, Lloyd RV. Leptin signal transduction in the HP75 human pituitary cell line. Pituitary. 2000;3(4):211-220.
42. Kristiansen M T, Clausen LR, Nielsen S, et al. Expression of leptin receptor iso-forms and effects of leptin on the proliferation and hormonal secretion in human pituitary adenomas. Horm Res. 2004;62(3):129-136.
43. Sone M, Osamura RY. Leptin and the pituitary. Pituitary. 2001;4(1-2):15-23.
44. Popovic V, Damjanovic S, Dieguez C, Casanueva F F. Leptin and the pituitary. Pituitary. 2001;4(1-2):7-14.
45. Roth C, Salomon F, Watts GF, Hesp R, Sonksen PH. Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the down-regulation of appetite. Eur J Endocrinol. 1998;138(1):89-91.